ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.59
-0.21 (-0.96%)
At close: Oct 6, 2025, 4:00 PM EDT
21.59
0.00 (0.00%)
After-hours: Oct 6, 2025, 4:43 PM EDT
ACADIA Pharmaceuticals Employees
As of December 31, 2024, ACADIA Pharmaceuticals had 654 total employees, including 653 full-time and 1 part-time employees. The number of employees increased by 56 or 9.36% compared to the previous year.
Employees
654
Change (1Y)
56
Growth (1Y)
9.36%
Revenue / Employee
$1,557,928
Profits / Employee
$339,694
Market Cap
3.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 654 | 56 | 9.36% |
| Dec 31, 2023 | 598 | 85 | 16.57% |
| Dec 31, 2022 | 513 | -1 | -0.19% |
| Dec 31, 2021 | 514 | -87 | -14.48% |
| Dec 31, 2020 | 601 | 98 | 19.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACAD News
- 9 hours ago - ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish - Seeking Alpha
- 4 days ago - Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - Business Wire
- 12 days ago - Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga
- 12 days ago - Acadia Pharmaceuticals' rare disease therapy fails late-stage trial - Reuters
- 12 days ago - Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - Business Wire
- 24 days ago - Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha